Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthenia Gravis (gMG)
SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other...
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), 15 mg, once daily, for the...
FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (pronounced as ‘ZEE-vah-skin’)...
FDA Approves Penpulimab-kcqx for the Treatment of Advanced Nasopharyngeal Carcinoma
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated...
Burnout and Stress Continue to Plague the Nursing Profession
The nursing workforce remains under immense pressure due to stress, burnout, and persistent short staffing, according to a report released by Cross Country...
Milwaukee Closes More Schools to Address Lead Crisis
WEDNESDAY, April 30, 2025 — Milwaukee will temporarily close two more elementary schools as it works to tackle a lead crisis in its public school...
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors...
Mental Health, Neurodevelopmental Diagnoses in Publicly Insured Children on the Rise
The percentage of publicly insured children receiving any mental health or neurodevelopmental disorder diagnosis significantly increased between 2010 and...
Adult Acne Linked to Higher Risk for Eating Disorders
Adults with acne have a higher likelihood of having eating disorders, according to a letter to the editor published online April 16 in the Journal...
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA), according to a study published online...
Martinelli Recalls 170,000 Apple Juice Bottles for Possible Toxin
WEDNESDAY, April 30, 2025 — More than 170,000 bottles of Martinelli’s apple juice are being recalled due to possible contamination with a mold-related...
New HHS Ad Campaign Urges Americans to 'Take Back Your Health'
WEDNESDAY, April 30, 2025 — U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is preparing to launch a multimillion-dollar public health...
Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application for Elamipretide
NEEDHAM, Mass., April 29, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...
Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 - Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating...
Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC
LAS VEGAS, April 26, 2025 – Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating...
Where Have All The Insects Gone — And Why?
SATURDAY, April 26, 2025 — From beetles to moths, leafhoppers and butterflies, the world's insects are vanishing at a breakneck pace. Since 2017,...
Health Fixer Issues Voluntary Nationwide Recall of Male Ultra, Malextra, Electro Buzz, Ultra Armor and Male Ultra Pro
April 25, 2025 – Tempe, AZ, HEALTH FIXER is voluntarily recalling all lots of dietary supplements by the name of Male Ultra, Malextra, Electro Buzz,...
Recently Added
Recently added consumer and prescribing information: Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten, Aucatzyl
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Imaavy Imaavy (nipocalimab-aahu) is a neonatal Fc receptor (FcRn) blocker used for the treatment of generalized myasthenia gravis
- Atzumi Atzumi (dihydroergotamine mesylate) is a nasal powder formulation of the ergotamine derivative dihydroergotamine mesylate for the acute...
- Zevaskyn Zevaskyn (prademagene zamikeracel) is an autologous, cell sheet-based gene therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...